Opioids and adverse outcomes in elderly chronic obstructive pulmonary disease patients

To the Editor:
We read with interest the study by Vozoris et al. [1] describing the risk of adverse outcomes associated with opioid use in elderly chronic obstructive pulmonary disease (COPD) patients. There is currently a strong debate on the prescription of opioids in patients with COPD. While several studies seemed to demonstrate the harmlessness of opioids in this population [2–4], two recent studies including the one by Vozoris et al. [1] challenge this result [5]. The large number of included patients and the excellent method used in these two studies strongly support the idea of an excess morbidity or mortality associated with the opioid use in COPD patients. There is, however, one limitation that needs to be taken into consideration. Vozoris et al. [1] explain that patients receiving palliative care in the year prior to the index date were excluded. This seems appropriate since the use of morphine is recommended in the treatment of end-of-life dyspnoea. Nevertheless, we believe that this exclusion criterion is not strict enough to avoid a bias in the analysis and interpretation of mortality risk. Indeed, discussion of palliative care in COPD patients often arises in the context of acute respiratory failure [6]. Over half of pulmonologists claimed that end-of-life decisions in COPD patients occur during/after a major exacerbation [7, 8]. It is unlikely that patients receiving opioid drugs following a recent end-of-life decision were excluded from the study by Vozoris et al. [1]. This potential bias may explain why no significant association was observed between opioid use and intensive care unit admissions in both the primary analysis and the sensitive analysis. Thus, the mortality results should be interpreted with caution.

In conclusion, the debate on the safety of morphine in COPD patients will remain open until further prospective studies refute or confirm the results published by Vozoris et al. [1]. Based on table 3 in their article [1], a randomised placebo controlled study would require the inclusion of 17,664 patients to detect a significant difference (alpha=0.05 and power=0.8) in COPD or pneumonia-related mortality, while 7,746 patients would be necessary to detect a difference in all-cause mortality.

@ERSpublications
Opioids in patients with COPD: results of mortality should be interpreted with caution regarding exclusion criteria http://ow.ly/lJbd304nC36

Damien Viglino1,2 and Maxime Maignan1,2
1University Hospital Grenoble Alps – Emergency Dept and Mobile Intensive Care Unit, Grenoble, France. 2INSERM U1042, HP2 Laboratory, University Grenoble Alps, Grenoble, France.

Correspondence: Damien Viglino, Service des Urgences, CHU Grenoble Alpes, CS 10217, 38043 Grenoble cedex 9, France. E-mail: dviglino@chu-grenoble.fr

Received: Aug 12 2016 | Accepted: Aug 14 2016

Conflict of interest: None declared.

References
We thank D. Viglino and M. Maignan for their interest in our manuscript [1] and for their insightful comments. They raise a valid point that our mortality results may have been influenced by the potentially confounding effects of palliative care receipt on or following the index date. While we excluded individuals receiving palliative care in the year prior to the index date, we did not do so on or after the index date for practical methodological reasons. However, several points should be considered. First, Viglino and Maignan write that the decision to palliate in chronic obstructive pulmonary disease (COPD) often arises in the context of an acute respiratory exacerbation. Our propensity score model included whether or not a recent acute respiratory exacerbation occurred in the 30 days prior to the index date, and opioid users and nonusers were well balanced on that variable after propensity score weighting [1]. Second, increased respiratory-related and all-cause mortality were found not only among users of opioid-only agents but also among users of combination opioid/nonopioid formulations [1]. Opioids combined with paracetamol or aspirin are unlikely to be used for purposes of palliation and such agents represent ~90% of incident opioid use among older adults with COPD [2]. Third, while the possible residual inclusion of individuals receiving palliative care among opioid users may potentially explain the finding of increased mortality, this would be unlikely to explain why risks of outpatient respiratory exacerbations and emergency visits for COPD or pneumonia were also greater among opioid users. If there was residual inclusion of individuals with recent end-of-life decisions among opioid users in our study, this would have been likely to bias the intensive care admission outcome towards being significantly decreased among opioid users, and not rendered a nonsignificant association, as Viglino and Maignan propose.

Viglino and Maignan indicate that further clinical trials are needed to help clarify the issue of the respiratory safety of opioids in COPD. However, clinical trials in isolation may not provide a complete picture regarding possible drug harms. As Viglino and Maignan suggest, clinical trials often include insufficient numbers of participants to identify potential risks of drug harm that are likely to occur in a minority of individuals, and trials involving participant numbers that Viglino and Maignan outline would be likely to be cost-prohibitive and unfeasible. Furthermore, clinical trials are commonly characterised by other features that limit their ability to evaluate possible drug harms: exclusion of individuals at risk of drug-related adverse events (such as older adults and those with comorbid illnesses); examination of limited drug dosing; and significant participant drop-out. Observational studies, such as ours, can overcome some of these limitations by including larger numbers of individuals, from the broader population, and “real-world” drug use. As a result, observational drug studies can help complement findings from clinical trials and both together can provide useful information to better guide therapy decision-making [3].